The syndrome affects 1% of the population, and is probably not a singl
e disease. Clinical observation has identified symptom ''dimensions,''
perhaps related to differing pathophysiologic processes. Meanwhile, p
harmacologic investigation implies that schizophrenia cannot be pinned
to any single neurotransmitter system. Techniques of brain imaging ar
e now providing glimpses of cognitive dysfunction.